Trial Profile
Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis ("ProDERM Study")
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Dermatomyositis
- Focus Registrational; Therapeutic Use
- Acronyms ProDERM
- Sponsors Octapharma
- 17 Jan 2024 Results examining the safety and tolerability of IVIg, published in the Arthritis Research and Therapy
- 15 Nov 2023 Results of a post-hoc analysis assessing myositis autoantibodies as predictors of response to IVIG presented at the ACR Convergence 2023
- 03 Jun 2023 Post -hoc results presented at the 24th Annual Congress of the European League Against Rheumatism.